PULM
$1.28
Pulmatrix
PULM
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.19)
Revenue:  $0.00 Mil
Thursday
Feb 11
9:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PULM reports earnings?
Beat
Meet
Miss

Where is PULM's stock price going from here?
Up
Flat
Down
Stock chart of PULM
Analysts
Summary of analysts' recommendations for PULM
Score
Grade
Pivots
Resistance
$1.37
$1.33
$1.31

$1.27

Support
$1.25
$1.21
$1.19
Tweet
Growth
Description
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.